History
On March 11, 2020, the World Health Organization declared the coronavirus outbreak a global pandemic.
On March 15, 2020, the President of the Republic of Kazakhstan, Kassym-Jomart Tokayev, signed a decree introducing a state of emergency throughout the country.
On September 1, 2021, in his Address to the People of Kazakhstan titled “The Unity of the People and Systemic Reforms – a Solid Foundation for the Country’s Prosperity,” the Head of State emphasized the importance of establishing a national system for forecasting biological safety threats and developing domestic biopharmaceutical products.
In this context, on December 20, 2021, the Government of the Republic of Kazakhstan adopted a resolution establishing the Joint Stock Company “National Holding QazBioPharm” (hereinafter – the Holding), with 100% state participation in its charter capital.
The charter capital of the Holding was formed through the transfer of the state-owned block of shares in JSC “Research Center for Anti-Infectious Drugs.” The right to own and manage the state’s shares in the Holding was assigned to the Ministry of Health of the Republic of Kazakhstan.
Mission
To effectively manage legal entities in order to ensure biological safety and to meet the needs of the state and society for biopharmaceutical products.
Purpose and Vision
The primary purpose of JSC “National Holding QazBioPharm” is to ensure biological safety, promote sustainable development, and improve the infrastructure of the biopharmaceutical market, while fostering the advancement of biopharmaceutical science and industry.
The Holding’s vision is based on the following principles:
- Enhancing the competitiveness and economic efficiency of the Holding and its subsidiaries;
- Applying best international practices in corporate governance across the Holding and its affiliated companies;
- Ensuring transparency and integrity, including the active involvement of independent directors.